ESTRO 2025 - Abstract Book

S2913

Physics - Dose prediction, optimisation and applications of photon and electron planning

ESTRO 2025

improved in EMBRACE-II compared to EMBRACE-I. No statistically significant difference in V43Gy/PTV dose conformity was observed between the 5 EMBRACE-II groups at a significance level of 0.05 (p = 0.11). 643 patients (47%) had SIB to 1927 pathological nodes. Median[IQR] difference in dose to 98% of the nodal clinical target volume and nodal PTV was 4.7[3.8 – 5.4]Gy. Bowel volume irradiated to 40Gy (V40Gy) increased with larger elective nodal volume. The presence of nodal SIB did not have a statistically significant effect on bowel V40Gy.